Rani Therapeutics Holdings Inc
Change company Symbol lookup
Select an option...
RANI Rani Therapeutics Holdings Inc
RENE Cartesian Growth Corporation II
DTCFF Defence Therapeutics Inc
STKH Steakholder Foods Ltd
ADBE Adobe Inc
FATP Fat Projects Acquisition Corp
LGVC LAMF Global Ventures I Corp
SECO Secoo Holding Ltd
SGBXV Safe & Green Holdings Corp
CAH Cardinal Health Inc
Go

Health Care : Pharmaceuticals | Small Cap Growth
Company profile

Rani Therapeutics Holdings, Inc. is a clinical-stage biotherapeutics company. The Company is focused on advancing technologies to enable the administration of biologics and drugs orally, to provide patients, physicians, and healthcare systems with a convenient alternative to painful injections. The Company has developed a drug-agnostic oral delivery platform, the RaniPill capsule, which is designed to deliver a variety of drug substances, including large molecules, such as peptides, proteins, and antibodies. The RaniPill capsule, the RaniPill GO, is designed to deliver up to a three micrograms (mg) dose of drug with high bioavailability. The capsule includes a coating designed to withstand stomach acid but dissolve in the jejunum portion of the small intestine. Its pipeline includes RT-101, RT-102, RT-105, RT-110 and RT-111. Its RT-101 is an Octreotide for the treatment of NETs and acromegaly. It manufactures and assembles RaniPill capsules at its facility in San Jose, California.

Price
Delayed
$2.88
Day's Change
0.12 (4.35%)
Bid
--
Ask
--
B/A Size
--
Day's High
2.93
Day's Low
2.76
Volume
(Light)

Today's volume of 8,138 shares is on pace to be much lighter than RANI's 10-day average volume of 55,034 shares.

8,138

Company Profile

Rani Therapeutics Holdings, Inc. is a clinical-stage biotherapeutics company. The Company is focused on advancing technologies to enable the administration of biologics and drugs orally, to provide patients, physicians, and healthcare systems with a convenient alternative to painful injections. The Company has developed a drug-agnostic oral delivery platform, the RaniPill capsule, which is designed to deliver a variety of drug substances, including large molecules, such as peptides, proteins, and antibodies. The RaniPill capsule, the RaniPill GO, is designed to deliver up to a three micrograms (mg) dose of drug with high bioavailability. The capsule includes a coating designed to withstand stomach acid but dissolve in the jejunum portion of the small intestine. Its pipeline includes RT-101, RT-102, RT-105, RT-110 and RT-111. Its RT-101 is an Octreotide for the treatment of NETs and acromegaly. It manufactures and assembles RaniPill capsules at its facility in San Jose, California.

Valuation Ratios

Price/Earnings (TTM)
--
Price/Sales (TTM)
--
Price/Book (MRQ)
5.69x
Price/Cash Flow (TTM)
--
TTM = Trailing Twelve Months
MRQ = Most Recent Quarter

Price Performance

Historic Growth and Share Detail

Historic Growth

No historic growth available.

Short Interest

August 2023
Current Month
975.0K
Previous Month
959.4K
Percent of Float
7.77%
Days to Cover
34.7774 Days

Share Information

RANI is in a share class of common stock
Float
12.5M
Shares Outstanding
49.6M
Institutions Holding Shares
37
12.14%

Financial Statements

Balance sheet

Values displayed are in thousands.

Income statement

Values displayed are in thousands.

Cash flow

Values displayed are in thousands.

Company Officers

  • Mir ImranChmn.
  • Talat ImranCEO
  • Svai S. SanfordCFO
  • Mir HashimCSO
  • Eric GroenCounsel

Address

Insider Trading

During the most recent quarter, 80K shares were bought in insider trading.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Insider trading information report provided by Copyright © 2023. All rights reserved.

Reuters content is the intellectual property of Reuters. Any copying, republication or redistribution of Reuters content, including by caching, framing or similar means, is expressly prohibited without the prior written consent of Reuters. Reuters is not liable for any errors or delays in content, or for any actions taken in reliance on any content. Reuters, Reuters Logo and the Sphere Logo are trademarks and registered trademarks of the Reuters Group of companies around the world.

Data is provided for information purposes only and is not intended for trading purposes. Reuters shall not be liable for any errors or delay in the content, or for any action taken in reliance on any content. The RIC or Reuters Instrument Code set has been developed and maintained by Reuters and is the intellectual property of Reuters.